Freenome (NASDAQ:FRNM) Given Average Recommendation of “Moderate Buy” by Analysts

Freenome (NASDAQ:FRNM) has been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $18.00.

FRNM has been the subject of several research analyst reports. Guggenheim assumed coverage on Freenome in a report on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective for the company. BTIG Research assumed coverage on Freenome in a research note on Monday, August 17th. They set a “buy” rating and a $17.00 target price on the stock. Weiss Ratings started coverage on Freenome in a research note on Monday. They issued a “sell (d+)” rating for the company. Leerink Partners initiated coverage on shares of Freenome in a report on Friday, August 14th. They issued an “outperform” rating and a $18.00 price target on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Freenome in a research report on Monday, August 17th. They set a “buy” rating and a $17.00 price objective on the stock.

Freenome Price Performance

Shares of NASDAQ FRNM traded up $0.21 during trading hours on Tuesday, hitting $13.99. The company’s stock had a trading volume of 475,972 shares, compared to its average volume of 870,695. Freenome has a 12 month low of $9.97 and a 12 month high of $14.26. The stock has a market capitalization of $114.16 million, a PE ratio of -233.13 and a beta of 0.35.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.